TScan Therapeutics IncNASDAQ:TCRX
- LAST PRICE1.8200
- TODAY'S CHANGE (%)0.0100 (0.5525%)
- Bid / Lots1.6100/ 5
- Ask / Lots1.8700/ 2
- Open / Previous Close1.7900 / 1.8100
- Day Range
- 52 Week Range
- Volume72,280
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TCRX |
|---|---|---|
| 09:32 ET | 1909 | 1.7528 |
| 09:33 ET | 100 | 1.82 |
| 09:37 ET | 648 | 1.8296 |
| 09:39 ET | 100 | 1.82 |
| 09:48 ET | 4100 | 1.82 |
| 09:50 ET | 100 | 1.82 |
| 09:51 ET | 3400 | 1.8202 |
| 09:53 ET | 300 | 1.82 |
| 09:57 ET | 100 | 1.82 |
| 10:02 ET | 100 | 1.82 |
| 10:04 ET | 100 | 1.82 |
| 10:09 ET | 300 | 1.821 |
| 10:11 ET | 3800 | 1.82 |
| 10:13 ET | 300 | 1.82 |
| 10:15 ET | 100 | 1.83 |
| 10:18 ET | 100 | 1.82 |
| 10:20 ET | 200 | 1.82 |
| 10:22 ET | 800 | 1.8205 |
| 10:26 ET | 101 | 1.83 |
| 10:27 ET | 500 | 1.82 |
| 10:29 ET | 800 | 1.82 |
| 10:47 ET | 1200 | 1.8208 |
| 10:49 ET | 1848 | 1.82 |
| 11:03 ET | 200 | 1.8385 |
| 11:05 ET | 100 | 1.8201 |
| 11:07 ET | 1600 | 1.82 |
| 11:12 ET | 1300 | 1.75 |
| 11:14 ET | 100 | 1.785 |
| 11:18 ET | 100 | 1.82 |
| 11:20 ET | 400 | 1.82 |
| 11:21 ET | 300 | 1.82 |
| 11:23 ET | 100 | 1.82 |
| 11:32 ET | 100 | 1.82 |
| 11:56 ET | 5300 | 1.8 |
| 12:06 ET | 100 | 1.82 |
| 12:08 ET | 800 | 1.8202 |
| 12:10 ET | 200 | 1.82 |
| 12:12 ET | 200 | 1.82 |
| 12:14 ET | 300 | 1.82 |
| 12:15 ET | 1772 | 1.82 |
| 12:32 ET | 1300 | 1.82 |
| 12:33 ET | 200 | 1.81 |
| 12:35 ET | 200 | 1.82 |
| 12:37 ET | 100 | 1.82 |
| 12:39 ET | 100 | 1.82 |
| 12:42 ET | 300 | 1.82 |
| 12:44 ET | 100 | 1.82 |
| 12:46 ET | 100 | 1.82 |
| 12:48 ET | 100 | 1.82 |
| 12:50 ET | 100 | 1.82 |
| 12:51 ET | 200 | 1.82 |
| 12:53 ET | 100 | 1.81 |
| 12:55 ET | 368 | 1.82 |
| 12:57 ET | 200 | 1.82 |
| 01:00 ET | 100 | 1.82 |
| 01:02 ET | 100 | 1.81 |
| 01:04 ET | 300 | 1.82 |
| 01:06 ET | 200 | 1.82 |
| 01:08 ET | 100 | 1.82 |
| 01:09 ET | 200 | 1.82 |
| 01:11 ET | 136 | 1.82 |
| 01:13 ET | 100 | 1.82 |
| 01:15 ET | 100 | 1.82 |
| 01:18 ET | 164 | 1.82 |
| 01:20 ET | 100 | 1.82 |
| 01:22 ET | 200 | 1.82 |
| 01:24 ET | 301 | 1.82 |
| 01:26 ET | 200 | 1.82 |
| 01:27 ET | 100 | 1.82 |
| 01:29 ET | 300 | 1.82 |
| 01:36 ET | 1000 | 1.82 |
| 01:44 ET | 1100 | 1.83 |
| 01:47 ET | 800 | 1.83 |
| 01:49 ET | 100 | 1.84 |
| 02:00 ET | 1000 | 1.8201 |
| 02:20 ET | 3101 | 1.82 |
| 02:21 ET | 2000 | 1.83 |
| 02:34 ET | 1100 | 1.8209 |
| 02:43 ET | 5047 | 1.83 |
| 02:45 ET | 5000 | 1.8405 |
| 02:50 ET | 100 | 1.85 |
| 03:48 ET | 3133 | 1.85 |
| 03:53 ET | 171 | 1.85 |
| 03:55 ET | 3106 | 1.83 |
| 03:57 ET | 1175 | 1.82 |
Jan 23, 2023
TScan Therapeutics Says US FDA Clearance Received for 3 Investigational New Drug Applications for Cancer Therapies, from 10:52AM ET on Monday Jan 23, 2023 by MT Newswires
10:52AM ET on Monday Jan 23, 2023 by MT NewswiresBRIEF-TScan Therapeutics Announces FDA Clearance Of Three Investigational NDA, from 7:49AM ET on Monday Jan 23, 2023 by Thomson Reuters
7:49AM ET on Monday Jan 23, 2023 by Thomson ReutersTScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors, from 7:00AM ET on Monday Jan 23, 2023 by GlobeNewswire
7:00AM ET on Monday Jan 23, 2023 by GlobeNewswire
Jan 5, 2023
BRIEF-Tscan Therapeutics Announces 2023 Clinical Plans, from 7:20AM ET on Thursday Jan 05, 2023 by Thomson Reuters
7:20AM ET on Thursday Jan 05, 2023 by Thomson ReutersTScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress, from 7:00AM ET on Thursday Jan 05, 2023 by GlobeNewswire
7:00AM ET on Thursday Jan 05, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TScan Therapeutics Inc | 43.8M | -0.7x | --- |
OncoCyte Corp | 46.3M | -0.6x | --- |
Erytech Pharma SA | 38.6M | 0.0x | --- |
Sigilon Therapeutics Inc | 22.8M | -0.4x | --- |
Avalo Therapeutics Inc | 36.6M | -0.7x | --- |
Lipocine Inc | 48.7M | 11.8x | --- |
Company Information
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company's platform discovers anti-cancer TCRs from patients with responses to immunotherapy and also manufactures TCR-T therapies. It is also advancing five solid tumor programs: TSC-200, TSC-204, TSC-201, TSC-202, and TSC-203.
Contact Information
- Headquarters
- 880 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 857-399-9500
- Fax
- 302-531-3150
Executives
- Non-Executive Independent Chairman
- Timothy Barberich
- President, Chief Executive Officer, Director
- David Southwell
- Chief Financial Officer, Treasurer
- Brian Silver
- Chief Scientific and Operations Officer
- Gavin Macbeath
- Vice President - Finance
- Leiden Dworak
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.8M |
|---|---|
Revenue (TTM) | $13.3M |
Shares Outstanding | 24.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.58 |
Book Value | $6.72 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -467.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
